|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.
|
30439718 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, it is unclear whether similar mechanisms of doxorubicin resistance are involved in colorectal cancer (CRC).
|
29701752 |
2018 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Indeed, many genes, including genes encoding drug transporters (ABCB1), drug targets (SCN1A), drug-metabolizing enzymes (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins, may regulate the mechanisms of drug resistance in epilepsy.
|
29804481 |
2018 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population.
|
29198163 |
2018 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study investigates the effect of the Pgp inhibitor verapamil on the anticonvulsant effect of CBZ and its nanoparticulate formulation in the rat model of isoniazid-induced epilepsy.
|
29751140 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data indicate that the miR-338-5p/EGFR/ABCB1 regulatory loop plays a critical role in HCC, and a negative correlation between miR-338-5p and EGFR or ABCB1 was also detected in HCC clinical samples.
|
29527329 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review outlines the roles and principal mechanisms of p53 and P-gp mediated chemoresistance in HCC.
|
29772519 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We tested whether the uremic toxin indoxyl sulfate (IS), an endogenous ligand of the transcription factor aryl hydrocarbon receptor, could change the expression of the following liver transporters involved in drug clearance: <i>SLC10A1</i>, <i>SLC22A1</i>, <i>SLC22A7</i>, <i>SLC47A1</i>, <i>SLCO1B1</i>, <i>SLCO1B3</i>, <i>SLCO2B1</i>, <i>ABCB1</i>, <i>ABCB11</i>, <i>ABCC2</i>, <i>ABCC3</i>, <i>ABCC4</i>, <i>ABCC6</i>, and <i>ABCG2</i> We showed that IS increases the expression and activity of the efflux transporter P-glycoprotein (P-gp) encoded by <i>ABCB1</i> in human hepatoma cells (HepG2) without modifying the expression of the other transporters.
|
29222397 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.
|
29568938 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
|
29968951 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
All of these results indicate that Baicalein can reverse P-gp-mediated MDR in HCC and may thus be useful for the treatment of drug-resistant HCC.
|
29571250 |
2018 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
P-glycoprotein or membrane pump induced drug efflux and altered prosurvival Bcl-2 expression are key mechanisms for drug resistance leading to failure of chemotherapy in HCC.
|
29208281 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using in vitro assays, we show that repeated miRNA treatments resulted in gradual reduction of HCC cell proliferation and reversal of doxorubicin resistance.
|
29758233 |
2018 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Multidrug resistance (MDR) due to overexpression of MDR1 is a major obstacle that hinders the treatment of hepatocellular carcinoma (HCC).
|
29563873 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the consequences of ABCB1/MDR1 loss-of-function in a common murine model for CAC (AOM/DSS).
|
28686677 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, a significantly positive association between RARγ and MDR1 was demonstrated in CRC tissue microarrays.
|
28272990 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
|
28667355 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expressions of MDR-associated protein topoisomerase II (Topo II) and P-glycoprotein (P-gp) in CRC tissues were detected by immunohistochemistry.
|
28816939 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
|
28302530 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma).
|
28502672 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between MDR1 C3435T polymorphism and colorectal cancer risk: A meta-analysis.
|
29390571 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of this present study was to investigate the reversal effect of BU on ABCB1-mediated multidrug resistance in colorectal cancer.
|
28624793 |
2017 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess whether [<sup>11</sup>C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [<sup>11</sup>C]flumazenil studies used to assess gamma-aminobutyric acid A receptors.
|
26661244 |
2017 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genetic polymorphism of ABCB1 rs1045642 was found to be associated with normalized OXC concentration and therapeutic efficacy in patients with epilepsy (P<0.05).
|
28837897 |
2017 |
|
Epilepsy
|
0.600 |
Therapeutic
|
disease |
RGD |
By compared to the epilepsy model group, the P-gp expression was not markedly attenuated by the inhibition of NF-κB activity with PDTC treatment, nevertheless with a decrease of NF-κB expression in this intervention group.
|
28303499 |
2017 |